Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Esaxerenone (Primary) ; Eplerenone
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 12 May 2019 Primary endpoint (Change from baseline in sitting systolic and diastolic blood pressure (5mg)) has been met, according to the results published in the Journal of Human Hypertension
- 12 May 2019 Primary endpoint (Change from baseline in sitting systolic and diastolic blood pressure (2.5mg)) has been met, according to the results published in the Journal of Human Hypertension
- 12 May 2019 Results published in the Journal of Human Hypertension